Articles by Jill Wechsler - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Jill Wechsler

Filling the Pharma Pipeline

FDA, NIH, and industry seek new strategies to spur drug development and promote access to therapies.
May 1, 2011

FDA, NIH, and industry seek new strategies to spur drug development and promote access to therapies.

Health-Reform Controversies

Health-reform controversies pose new challenges.
Apr 1, 2011

Courts and Congress seek to reshape policies and programs affecting drug costs and access.

Drug Safety and Shortages Challenge Manufacturers

As drug shortages make headlines, FDA tets the Sentinel safety system and its effect on healthcare
Mar 1, 2011

As drug shortages make headlines, FDA tests the Sentinel safety system and its effect on healthcare.

Congress to Scrutinize FDA Rules, Research Policies

FDA prepares for top-level changes while promoting transparency and product safety
Feb 1, 2011

FDA prepares for top-level changes while promoting transparency and product safety

Costs and Compliance Dominate Agenda for 2011

Top priorities for manufacturers include user fees, new health initiatives, and regulatory compliance.
Jan 1, 2011

Top priorities for manufacturers include user fees, new health initiatives, and regulatory compliance.

Biotech Manufacturers Face New Political Landscape

Changes on Capital Hill create uncertainty for healthcare reform, drug regulation, and biomedical research.
Dec 1, 2010

Changes on Capital Hill create uncertainty for healthcare reform, drug regulation, and biomedical research.

Backing Biosimilars

Nov 11, 2010

FDA has to address multiple technical and legal issues to bring similar versions of biotech therapies to market.

Biotech Manufacturers Anticipate CER Challenges

Comparative effectiveness poses challenges for drug manufacturers.
Nov 1, 2010

Comparative effectiveness poses challenges for drug manufacturers.

Biotech Companies Gain Support for Vaccine, Countermeasure Production

A new strategy to streamline vaccine development and oversight.
Oct 1, 2010

A new strategy to streamline vaccine development and oversight.

ADVERTISEMENT

ADVERTISEMENT

Click here